CrossBridge Bio pioneers dual-payload ADCs that combine a branched tripeptide EGCit linker with synergistic topoisomerase-1 inhibitor and ATR inhibitor payloads, aiming to deliver deeper, more durable antitumor responses while minimizing toxicity. Its lead candidate, CBB-120, targets TROP-2 and has shown potent, durable activity in preclinical models, including tumors resistant to existing ADC therapies. The program garnered significant scientific interest as the most-attended non-plenary session at the 2025 World ADC Conference. The company plans to complete IND-enabling studies and file an Investigational New Drug (IND) application in 2026, moving CBB-120 into first-in-human trials. A recently awarded $15 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) will fund GLP toxicology studies, manufacturing scale-up, and analytical development to reach that milestone. Beyond CBB-120, CrossBridge Bio intends to leverage its proprietary platform for additional dual-payload ADC programs that address cancers with limited treatment options. The $15 million non-dilutive grant represents its current disclosed funding and underscores external validation of its scientific approach.

Total raised

$25M

Funding rounds

2

Latest round

Grant

Latest activity

Nov 2025